Risperidone Long-Acting Injection
| Autor: | Delia Bishara, Catrin Fischetti, Anna Sparshatt, Victoria Cornelius, David Taylor, Arwel Thomas |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Administration Oral Atypical antipsychotic Injections Intramuscular Cohort Studies Young Adult Internal medicine medicine Humans Prospective Studies Medical prescription Young adult Prospective cohort study Aged Risperidone business.industry Proportional hazards model Age Factors Dopamine antagonist Middle Aged Surgery Psychiatry and Mental health Treatment Outcome England Psychotic Disorders Delayed-Action Preparations Schizophrenia Patient Compliance Female business Antipsychotic Agents Follow-Up Studies medicine.drug Cohort study |
| Zdroj: | The Journal of Clinical Psychiatry. 70:196-200 |
| ISSN: | 0160-6689 |
| Popis: | To evaluate outcomes of clinical use of risperidone long-acting injection (RLAI) and determine factors predicting continuation with treatment.This prospective, 3-year follow-up of consecutive patients started on treatment with RLAI in normal clinical practice between August 2002 and September 2003 obtained demographic and clinical data from case notes, prescription charts, and hospital computer records. To determine predictors of continuation, a proportional hazards regression (Cox) model was constructed.The study included 211 evaluable patients. Over 3 years, 84% of subjects discontinued RLAI; 27.7% of these switched to oral risperidone. The Cox model showed that younger age (p = .001), longer duration of illness (p = .001), inpatient status at initiation (p = .002), and an RLAI dose of 25 mg/2 weeks (p.001) predicted greater probability of discontinuation.A small proportion of patients initiated on treatment with RLAI continued for 3 years. Outcome is likely to be improved by targeting RLAI treatment at specific patient groups and by using a dose of more than 25 mg/2 weeks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|